1. Berger JS, Jordan CO, Lloyd-Jones D, Blumenthal RS. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol 2010;55:1169-77.
2. Danesh J, Whincup P, Walker M, et al. Low grade infl ammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199-204.
3. Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-40.
4. Pearson T, Mensah G, Alexander R, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
5. Scientific and Organizing Committee of the Russian Federation essay. The epidemiology of cardiovascular disease in different regions of Russia (ESSE-RF). Rationale and design of the study. Profilakticheskaya Meditsina 2013; 6: 25-34. Russian (Научно-организационный комитет проекта ЭССЕ-РФ. Эпидемиология сердечно-сосудистых заболеваний в различных регионах России (ЭССЕ-РФ). Обоснование и дизайин исследований. Профилактическая Медицина 2013;6:25-34).
6. Ridker PM. C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease. Clinical Chemistry 2009;55:2 209-15.
7. Woloshin S, Schwartz LM. Distribution of C-reactive protein values in the United States. N Engl J Med 2005;352:1611-3.
8. Wang Z, Hoy WE. Population Distribution Of High Sensitivity C-Reactive Protein Values in Aboriginal ustralians: A Comparison With Other Populations. Clin Biochem 2006;39(3):277-81.
9. Hutchinson WL, Koenig W, Frohlich M, et al. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem 2000;46:934-8.
10. Albert MA Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 2003;108:161-5.
11. Ford E, Giles W, Myers G, et al Mannino DM. C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999–2000. Clin Chem 2003;49:1353-7.
12. Nasermoaddel A, Sekine M. Kagamimori S. Gender Differences in Associations of C-Reactive Protein With Atherosclerotic Risk Factors and Psychosocial haracteristics in Japanese Civil Servants. Psychosomatic Medicine 2006;68:1:58-63.
13. Marques-Vidal P, Mazoyer E, Bongard V, et al. Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care 2002;25:1371-7.
14. Imhof A, Frohlich M, Loewel H, et al. Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. Clin Chem 2003;49:669-72.
15. Winston H, Koenig W, Frohlich M. Immunoradiometric Assay of Circulating C-Reactive Protein: Agerelated Values in the Adult General Population. Clinical Chemistry 2000;46:7 934-8.
16. Loucks EB, Sullivan LM, Hayes LJ, et al. Association of Educational Level with Inflammatory Markers in the Framingham Offspring Study. Am J Epidemiol 2006:163:7:622-8.
17. Nazmi A, Victora C. Socioeconomic and racial/ethnic differentials of C-reactive protein levels: a systematic review of population-based studies. BMC Public Health 2007;7:212.
18. Dhingra R, Gona P, Nam BH, et al. С-Reactive Protein, Inflammatory Conditions and Cardiovascular Disease Risk. Am J Med 2007;120:12: 1054-62.
19. Loucks EB, Sullivan L, Hayes L, et al. Association of Educational Level with Inflammatory Markers in the Framingham Offspring Study. Am J Epidemiol 2006;163:7:622-8.
20. Zhukova VA, Shalnova SA, Metelskaya VA, et al. The results of population-based study "Stress, aging and health in Russia". Kremlevskaya meditsina. Klinicheskiy Vestnik 2012: 1: 136-8. Russian (Жукова В.А., Шальнова С.А., Метельская В.А., и др. Результаты популяционного исследования «Стресс, старение и здоровье в России». Кремлевская медицина. Клинический Вестник 2012:1;136-8).
21. Wannamethee S, Lowe G, Shaper A, et al. Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J 2005;26(17):1765-73.
22. Averina M, Nilssen O, Arkhipovsky V, et al. C-reactive protein and alcohol consumption: Is there a Ushaped association? Results from a population-based study in Russia The Arkhangelsk study. Atherosclerosis 2006;188:309-15.
23. Han T, Sattar N, Williams K, et al. Prospective Study of C-Reactive Protein in Relation to the Development of Diabetes and Metabolic Syndrome in the Mexico City Diabetes Study. Diabetes Care 2002;25:2016-21.
24. Laaksonen D, Niskanen L, Nyyssonen K, et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004;47:1403-10.
25. Ford E. Body Mass Index, Diabetes, and C-Reactive Protein Among U.S. Adults. Diabetes Care 1999;22:1971-7.
26. Grundy S. Obesity, metabolite syndrome and coronary atherosclerosis. Circulation 2002;105:26-98.
27. Indulekha K, Surendar J, Mohan V. C-Reactive Protein, Tumor Necrosis Factor-α, Interleukin-6, and Vascular Cell Adhesion Molecule-1 Levels in Asian Indians with Metabolic Syndrome and Insulin Resistance (CURES-105). J Diabetes Sci Technol 2011;5:4:982-8.
28. Morrow D, Lemos J. Benchmarks for the Assessment of Novel Cardiovascular Biomarkers. Circulation 2007;115:949-52.
29. Sesso HD, Burning GE, Rafai N, et al. C-reactive protein and the risk of development hypertension. JAMA 2003;290:2945-51.
30. Bautista LE, Vera LM, Arenas IA, et al. Independent association between inflammatory markers (Creactive protein, interleukin 6 and TNF-alpha) and essential hypertension. J Hum Hypertens 2005; 19 (2): 149-54.
31. Cifcova R, Frohlich J, Skodova Z, et al. C-reactive protein and the risk of developing hypertension. A population study. J Hypertens 2004;22:262.
32. Zacho J, Tybjærg-Hansen A, Jensen JS, et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. October 30, 2008;359:1897-908.
33. Ridker P, Charles H, Hennekens M, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
34. Berger JS, Jordan CO, Lloyd-Jones D, Blumenthal RS. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol 2010;55:1169-77.
35. Bekbosynova MS, Nikitina TY, Golitsyn SP, et al. The level of C-reactive protein and the incidence of autoantibodies against β1-adrenoceptor in patients with supraventricular tachyarrhythmias. Kardiologiya 2006; 7: 55-61. Russian (Бекбосынова М.С., Никитина Т.Я., Голицин С.П. и др. Уровень С-реактивного белка и частота выявления аутоантител к β1-адренорецепторам у больных с наджелудочковыми тахиаритмиями. Кардиология 2006;7:55-61).
36. de Torres JP, Cordoba-Lanus E, López-Aguilar C, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006;27:5:902-7.